Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A 62-year-old man was diagnosed with unresectable locally advanced pancreatic cancer and was treated with mFOLFIRINOX for 9 months. Despite the tumor remarkable shrinkage, the contact with the nerve plexus around the SMA was not diminished. After confirming no distant metastasis with staging laparoscopy, radiotherapy with S-1 was performed. However, even after chemoradiotherapy, CT findings around the SMA showed no significant changes. Eleven months after the initial treatment, conversion surgery was conducted. The nerve plexus was successfully separated from the artery, allowing for a curative resection via pancreaticoduodenectomy. The histopathological findings revealed no residual cancer cells, and post-treatment classification was complete response. The patient remained healthy with no recurrence for over 13 months since the surgical resection. Preoperative CT findings sometimes suggest residual cancer around the nerve plexus even after treatment. However, as this case shows, the suspicion of residual cancer on imaging sometimes reveals no residual cancer, and the final decision may be determined by surgical resection.

Download full-text PDF

Source

Publication Analysis

Top Keywords

residual cancer
16
nerve plexus
12
unresectable locally
8
locally advanced
8
advanced pancreatic
8
pancreatic cancer
8
surgical resection
8
cancer
6
case unresectable
4
cancer chemoradiotherapy
4

Similar Publications

Cervical cancer remains a significant cause of female mortality worldwide, primarily due to abnormal cell growth in the cervix. This study proposes an automated classification method to enhance detection accuracy and efficiency, addressing contrast and noise issues in traditional diagnostic approaches. The impact of image enhancement on classification performance is evaluated by comparing transfer learning-based Convolutional Neural Network (CNN) models trained on both original and enhanced images.

View Article and Find Full Text PDF

Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).

View Article and Find Full Text PDF

The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases.

View Article and Find Full Text PDF

We report a 43-year-old man with de novo metastatic testicular seminoma complicated by paraplegia from spinal cord compression due to retroperitoneal lymphadenopathy. Urgent retroperitoneal biopsy confirmed seminoma and, after the patient declined neurosurgical intervention, systemic chemotherapy was promptly initiated prior to delayed orchidectomy. Post-chemotherapy orchidectomy histology revealed minimal viable tumour and serial imaging showed a residual retroperitoneal mass with low-grade uptake on FDG-PET.

View Article and Find Full Text PDF

Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, has emerged as a transformative tool in precision oncology, providing real-time, minimally invasive characterizations of the tumor and tumor dynamics. While tissue biopsy is a critical tool for baseline diagnosis of malignancy, it is often limited by sampling constraints and an inability to capture tumor heterogeneity. In this study, we explored the clinical utility of serial ctDNA testing in guiding therapeutic decisions across a cohort of 30 patients with diverse solid tumors.

View Article and Find Full Text PDF